Watch More Highlights
Donna Kinzler, DNP, ACNP-BC, AOCNP, of the Allegheny Health Network Cancer Institute, discusses the SOPHIA study, which APs need to be aware for their practice. The phase III trial compared margetuximab-cmkb plus chemotherapy (CTX) vs trastuzumab plus CTX in patients with HER2-positive metastatic breast cancer after prior anti-HER2 therapies (Abstract PD8-01).